Supplementary Material

# Supplementary Figures and Tables

## Supplementary Figures



**Supplementary Figure 1.** Patient flow-chart.

****

**Supplementary Figure 2**. Death censored graft survival in patients with normal, ABMRh and IFTA biopsies. Kaplan-Meier survival curves representing death censored graft survival. ABMRh: antibody-mediated rejection histology; IFTA: interstitial fibrosis and tubular atrophy.

## Supplementary Tables

**Supplementary Table 1**.

(**A**) Comparison of post-transplant non-HLA antibodies between ABMRhDSApos and ABMRhDSAneg cases.

|  |  |  |  |
| --- | --- | --- | --- |
|  | **ABMRhDSApos (n=38)** | **ABMRhDSAneg (n=14)** | **p-value** |
| Post-transplant AT1R-Ab (yes, %) | 10 (26.3%) | 2 (14.3%) | 0.48 |
| Post-transplant ETAR-Ab (yes, %) | 6 (15.8%) | 1 (7.1%) | 0.66 |
| Post-transplant MICA-Ab (yes, %) | 6 (15.8%) | 2 (14.3%) | 1.00 |
| Post-transplant EC-XM (positive, %) $ | 4 (13.3%) | 0 (0%) | 0.30 |

$ From 30 ABMRhDSApos and 13 ABMRhDSAneg cases.

ABMRh: antibody-mediated rejection histology; AT1R-Ab: antibodies against angiotensin II type 1 receptor; EC-XM: crossmatch with primary aortic endothelial cells; ETAR-Ab: antibodies against endothelin-1 type A receptor; MICA-Ab: antibodies against major histocompatibility complex class I related chain A.

(**B**) Comparison of post-transplant HLA and non-HLA antibodies between ABMRhDSApos and non-ABMRhDSApos cases (normal histology, IFTA and ABMRhDSAneg cases).

|  |  |  |  |
| --- | --- | --- | --- |
|  | **ABMRhDSApos (n=38)** | **No ABMRhDSApos (n=80)** | **p-value** |
| Post-transplant HLA-DSA (yes, %) | 38 (100%) | 11 (13.8%) | **<0.001** |
| Post-transplant AT1R-Ab (yes, %) | 10 (26.3%) | 20 (25%) | 0.88 |
| Post-transplant ETAR-Ab (yes, %) | 6 (15.8%) | 13 (16.3%) | 0.95 |
| Post-transplant MICA-Ab (yes, %) | 6 (15.8%) | 9 (11.3%) | 0.56 |
| Post-transplant EC-XM (positive, %) # | 4 (13.3%) | 4 (5.5%) | 0.23 |

#30 ABMRhDSApos and 73 non-ABMRhDSApos cases.

AT1R-Ab: antibodies against angiotensin II type 1 receptor; EC-XM: crossmatch with primary aortic endothelial cells; ETAR-Ab: antibodies against endothelin-1 type A receptor; HLA-DSA: HLA donor-specific antibodies; MICA-Ab: antibodies against major histocompatibility complex class I related chain A.